Last updated on May 2018

Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Brief description of study

This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.

Detailed Study Description

This is a phase 1, open-label, dose-escalation, safety study evaluating up to 3 dose levels of ANX007 administered as single IVT injections. Approximately 9 to 15 eligible participants are enrolled into one cohort each. All participants receive ANX007 in an open-label manner. The primary objective is to evaluate the safety and tolerability of a single intravitreal (IVT) injection of ANX007 in participants with primary open-angle glaucoma. Secondary objectives are to evaluate the serum pharmacokinetics (PK) and immunogenicity. An exploratory objective will evaluate the pharmacodynamic (PD) effect of ANX007 on serum C1q activity.

Clinical Study Identifier: NCT03488550

Contact Investigators or Research Sites near you

Start Over

David Wirta, MD

Eye Research Foundation
Newport Beach, CA United States
  Connect »

Yang Sun, MD

Byers Eye Institute at Stanford University
Palo Alto, CA United States
  Connect »